Future studies are warranted to confirm these interesting results and to assess the potential role of PD-L1 checkpoint blockade therapy in type I EOC, particularly in ovarian clear cell carcinoma and mucinous carcinoma, which are relatively resistant to conventional chemotherapy regimens (Del Carmen et al., 2012; Winter et al., 2007). Here, CD274 is linked to ovarian clear cell cancer.